Table 1 Characteristics of 202 patients with pediatric- and adult-onset Crohn’s disease according to the Montreal classification[22] regarding NOD2 genotype at latest follow-up
Patients | Pediatric-onset CD (≤18 y) | Adult-onset CD (>18 y) | ||||
|---|---|---|---|---|---|---|
n=202 | n=85 | n=117 | ||||
NOD2genotype | Main variants | Wild-type | p-value | Main variants | Wild-type | p-value |
Number: n (%) | 37 (44%) | 48 (56%) | 47 (40%) | 70 (60%) | 0.67 | |
1 variant allele | 23 (27%) | 37 (32%) | ||||
2 variant alleles | 14 (16%) | 10 (9%) | 0.12 | |||
homozygous variant alleles | 7 (8%) | 3 (3%) | 0.099 | |||
Gender: female/male (%) | 57/43 | 38/62 | 0.08 | 51/49 | 59/41 | 0.39 |
Age: year | ||||||
mean/SD | 26/13.0 | 22.7/12.6 | 0.26 | 47.3/14.3 | 46.5/13.4 | 0.67 |
median/interquartile range | 22/17-35 | 20/15-26 | 0.18 | 46/36-62 | 45/36-54 | 0.78 |
average disease duration/SD | 12.8/11.2 | 11.3/10.5 | 0.63 | 16.2/11.3 | 16.5/10.3 | 0.89 |
Age at diagnosis: year | ||||||
mean/SD | 13.9/3.3 | 12.1/4.9 | 0.07 | 31.5/10.0 | 30.5/10.6 | 0.49 |
median/interquartile range | 15.0/12-17 | 13.0/9-17 | 0.18 | 27/23-33 | 29/24-38 | 0.32 |
Localization: n (%) | ||||||
L1 ileal | 9 (24%) | 12 (25%) | 1.0 | 18 (38%) | 14 (21%) | 0.058 |
L2 colonic | 3 (8%) | 13 (27%) | 0.048* | 4 (8%) | 11 (16%) | 0.27 |
L3 ileocolonic | 26 (68%) | 23 (48%) | 0.048* | 25 (53%) | 41 (61%) | 0.35 |
L4 isolated upper disease | 0 (0%) | 0 (0%) | 1.0 | 0 (0%) | 1 (1%) | 1.0 |
Upper GI involvement | 12 (32%) | 16 (33%) | 1.0 | 1 (2%) | 7 (10%) | 0.14 |
Behaviour: n (%) | ||||||
B1 non-stricturing/penetrating | 16 (43%) | 33 (69%) | 0.026* | 16 (35%) | 28 (41%) | 0.53 |
B2 stricturing | 15 (41%) | 6 (13%) | 0.005* | 22 (48%) | 20 (29%) | 0.051 |
B3 penetrating intern | 6 (16%) | 3 (6%) | 0.16 | 12 (26%) | 11 (16%) | 0.23 |
B3p penetrating perianal | 7 (19%) | 7 (15%) | 0.76 | 8 (17%) | 19 (28%) | 0.27 |